Maxim Group Initiates Coverage On NeuroOne Medical Tech with Buy Rating, Announces Price Target of $3
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Maxim Group analyst Anthony Vendetti initiates coverage on NeuroOne Medical Tech (NASDAQ:NMTC) with a Buy rating and announces Price Target of $3.
Maxim Group analyst Anthony Vendetti initiates coverage on NeuroOne Medical Tech (NASDAQ:NMTC) with a Buy rating and announces Price Target of $3.